AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: IBRX
Report Date: 2026-09-30
Full Report: https://amaly.io/stock/IBRX

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: This report evaluates ImmunityBio, Inc. (IBRX), a biotechnology company focused on immunotherapy development, against Shariah compliance standards. Key concerns arise from an exceptionally high interest income ratio due to minimal operating revenue, despite compliant debt and liquidity metrics. Business activities in healthcare R&D are permissible, with no non-compliant revenue streams identified. Overall, the company fails financial screening thresholds, leading to non-compliance across major indices. Investors may consider monitoring for revenue growth to improve future compliance.

Primary Compliance Concerns:
- Interest income ratio exceeds 471%, far above the 5% threshold across all standards
- Minimal operating revenue amplifies incidental non-halal income percentage
- Potential need for full purification of dividends due to income impurity

Purification Requirement: 100.00%
Index Inclusion: Not included in any major Shariah-compliant indices

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 24.1%
Liquidity Ratio: 2.8%
Interest Income Ratio: 471.1%
Purification Required: 100.00%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-11-30

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-18T12:00:00Z

---
Full interactive report: https://amaly.io/stock/IBRX
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.